Topic: antibody drug conjugates
Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.
Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
Wednesday, the FDA approved Padcev, a first-of-its kind antibody-drug conjugate. The product targets Nectin-4, a protein on the surface of cells.
AZ and Daiichi reported "impressive" data for DS-8201. J&J and Legend's CAR-T showed promise in multiple myeloma. South Korea jailed Samsung execs.
AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
AZ's oncology portfolio jumped 59% in Q1 sales, and China turned up 28% growth. So CEO Pascal Soriot figured its time for some long-term planning.
Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.
Daiichi is transitioning from CV and metabolic diseases to oncology, and it says now is the right time for a new CEO to take the helm.